Diligence memo · auto-generated · as of July 2, 2026

Pharma Solutions USA, Inc. DBA LighthouseAI

Pharma Solutions USA, Inc. DBA LighthouseAI looks over-valued against its niche peers and is at-risk on financing cadence.

WatchOverdue for a raise versus sector cadence — could be a bridge, a down round, or distress. Watch for the next filing.

Businessfiled

Pharma Solutions USA, Inc. DBA LighthouseAI operates in Pharmaceuticals, based in PENN VALLEY.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Pharma Solutions USA, Inc. DBA LighthouseAI has raised $7.2M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $6.7M on 2023-06-07.

Most recent recorded round closed around 2023-06-07.

Valuation (modeled)modeled

Provath models Pharma Solutions USA, Inc. DBA LighthouseAI at approximately $56M (range $7.7M–$155M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 1.72× the median modeled value of Series A Pharmaceuticals companies in 2022–2024 (64 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 6 months.

Last raise 3.1 yr ago; this sector typically re-raises about every 13 months.

Past due for a raise versus sector cadence — watch for distress or a bridge.

The last round stepped up 1.2× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 48% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 45% of those peers.

Closest niche peers: Hallux, Inc., Enalare Therapeutics Inc., Silver Creek Pharmaceuticals, Inc., NQ PE Project Stingray Parent, L.P., Acta Pharmaceuticals, Inc..

Peoplefiled

4 named people on file across officers, directors and signatories.

Risks & flagsmixed

Overdue for a raise versus sector norm — distress or bridge risk.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.